Rajen Doshi, MD
Urology · Festus, MONPI 1720060536
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Coloplast at 37.4% of the total. Reporting peaked in 2024 at $7,869 and has fallen 81.6% since, to $1,448 in 2025.
Across 181 payments — averaging $97.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$7K
- Teleflex LLC$3K
- Neotract Inc.$2K
- Procept Biorobotics Corporation$2K
- Calyxo, Inc.$762
- Boston Scientific$705
- plus $3K from 27 others
What the payments were for
- Consulting fees$5,00028%
- Travel & lodging$4,70127%
- Food & beverage$7,77244%
- Education$1421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 10 | $6,593 |
| Teleflex LLC | 30 | $3,062 |
| Neotract Inc. | 19 | $2,174 |
| Procept Biorobotics Corporation | 13 | $1,778 |
| Calyxo, Inc. | 7 | $762 |
| Boston Scientific | 17 | $705 |
| Astellas Pharma US Inc | 8 | $251 |
| BD | 11 | $206 |
| Urogen Pharma, Inc. | 4 | $187 |
| Cook Medical LLC | 1 | $173 |
| C. R. Bard, Inc. & Subsidiaries | 8 | $168 |
| Johnson & Johnson | 7 | $131 |
| Laborie Medical Technologies Corp. | 2 | $128 |
| Progenics Pharmaceuticals, Inc. | 1 | $123 |
| Ferring Pharmaceuticals Inc. | 4 | $114 |
| Olympus America Inc. | 1 | $112 |
| Convatec Inc. | 4 | $96 |
| Innovation Technologies Inc | 1 | $95 |
| SRS Medical Systems, Inc. | 1 | $93 |
| KARL Storz Endoscopy-america | 1 | $90 |
| AbbVie | 5 | $84 |
| Myriad Genetic Laboratories, Inc. | 4 | $83 |
| Tolmar, Inc. | 5 | $79 |
| Axonics, Inc. | 3 | $79 |
| Sumitomo Pharma America, Inc. | 4 | $74 |
| Medtronic | 2 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $37 |
| Bayer | 1 | $21 |
| Intuitive Surgical | 1 | $20 |
| Myovant Sciences Inc. | 1 | $18 |
| 180 Medical, Inc. | 1 | $17 |
| Insmed, Inc. | 1 | $14 |
| Urovant Sciences Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,215
- UroLift System$2,096
- AquaBeam Robotic System$1,512
- CVAC Aspiration System$725
- Cook$173
- Barrigel$139
- UroLift ATC System$135
- GreenLight XPS$131
- ZUSDURI$124
- PYLARIFY$123
- rezum Generator$119
- Optilume BPH Drug Coated Balloon Catheter$114
- Olympus$112
- GENERAL KIDNEY STONE DISEASE$110
- AMS$106
How this compares
$17,615 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 61 | $61,846 |
| GemtesaVibegron | 20 | $15,775 |
| Tamsulosin Hcl | 599 | $7,626 |
| Solifenacin Succinate | 88 | $2,934 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 160 | $1,560 |
| Finasteride | 124 | $1,466 |
| Trospium Chloride | 17 | $1,041 |
| Cefdinir | 94 | $826 |
| Silodosin | 24 | $752 |
| Cephalexin | 123 | $577 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $576 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 128 | $363 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 20 | $218 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $205 |
| Ampicillin Trihydrate | 21 | $195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $251 | $61,84661 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $74 | $15,77520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.
Other urology in Festus
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Samuel KuykendallKansas City$141K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
- Majdee IslamSaint Peters$64K
- Gerald AndrioleSaint Louis$64K
- Charles JonesSaint Louis$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.